IXICO plc New contract for imaging clinical trial services (1251K)
05 July 2017 - 4:00PM
UK Regulatory
TIDMIXI
RNS Number : 1251K
IXICO plc
05 July 2017
5 July 2017
IXICO plc
("IXICO" or the "Company")
IXICO signs new contract for specialist imaging clinical trial
services
Expansion of customer base, and endorsement of IXICO's expertise
in providing both PET and MR imaging services in neuroscience
clinical trials
IXICO plc (AIM: IXI), the digital technologies company serving
neuroscience, today announces that it has signed a new contract for
specialist imaging clinical trial services. The contract is for a
Phase II clinical trial of patients with Mild Cognitive Impairment
(MCI) due to Alzheimer's disease (AD). Sponsored by specialist
Spanish biotech company Araclon Biotech, a Grifols company, this
phase II of the study is designed to establish the dosage regimen
for the therapy, as well as confirm the treatment safety and
tolerability data obtained in phase I.
Using our TrialTracker(TM) digital platform, IXICO will collate
both PET and MRI scans acquired at specialist imaging centres
across Europe. This data will be then analysed using IXICO's patent
protected image analysis technology, which has been customised to
evaluate patient eligibility, assess target engagement and quantify
drug effects in AD patients.
Giulio Cerroni, Chief Executive of IXICO, commented: "We are
delighted to be working with Araclon Biotech which continues our
success in providing our customers with a solution that spans both
PET and MR imaging services. It is a great example of IXICO's
growing value to the biopharmaceutical industry and reinforces our
confidence in revenue growth this financial year."
Manuel Sarasa, Chief Scientific Officer of Araclon, commented:
"It is an important milestone for us to initiate phase II of
clinical trials for our Azheimer's vaccine -ABvac40- after
receiving approval from the Spanish Agency of Medicinal Products
and Medical Service. We are a little closer to achieving our goal,
so it is fundamental for us to incorporate the best-in-class
suppliers, such as IXICO, to work together in this amazing project
that is also supported by some Spanish institutions such as the
Zaragoza University."
For further information please contact:
IXICO plc
Giulio Cerroni, Chief Executive Tel: +44 20 3763
Officer 7499
Susan Lowther, Chief Financial Officer
Shore Capital (Nomad and Broker) Tel: +44 20 7408
Bidhi Bhoma / Edward Mansfield/James 4090
Wolfe
FTI Consulting Limited (Investor Tel: +44 20 3727
Relations) 1000
Simon Conway / Mo Noonan
About IXICO
IXICO is the digital technologies company serving neuroscience.
Our mission is to transform the pursuit of improving brain health
through the application of digital technologies to neuroscience.
IXICO's specialist data analytics services are used by the global
pharmaceutical industry to select participants for clinical trials,
assess the safety and efficacy of new drugs in development and in
post marketing surveillance. Our neurological disease focus
includes Alzheimer's disease, Huntington's disease, Multiple
Sclerosis, Parkinson's disease and our integrated digital platform
encompasses the entire drug development lifecycle. It is a scalable
and secure infrastructure for the capture and analysis of
regulatory compliant clinical data to enable sponsors to make
rapid, better informed decisions. IXICO is also collaborating with
partners to develop new companion digital health products targeted
at improving patient outcomes.
More information is available on www.IXICO.com
About Araclon Biotech
Araclon Biotech is a Grifols company specializes in researching
and developing therapies and diagnostic methods for Alzheimer's
disease (AD) and other neurodegenerative diseases. The company, in
which Grifols holds a majority stake, focuses on two research
areas: the early diagnosis of AD by means of detecting amyloid-beta
peptides in the blood, and the treatment of the disease using
immunotherapy (vaccines).
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTDMGGNVDRGNZM
(END) Dow Jones Newswires
July 05, 2017 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024